Low-dose Olaparib improves septic cardiac function by reducing ferroptosis via accelerated mitophagy flux

Sepsis is a dysregulated response to infection that can result in life-threatening organ failure, and septic cardiomyopathy is a serious complication involving ferroptosis. Olaparib, a classic targeted drug used in oncology, has demonstrated potential protective effects against sepsis. However, the...

Full description

Saved in:
Bibliographic Details
Main Authors: Ruixue Liu (Author), Fengjuan Li (Author), Shuai Hao (Author), Dongyao Hou (Author), Xue Zeng (Author), He Huang (Author), Gautam Sethi (Author), Jun Guo (Author), Chenyang Duan (Author)
Format: Book
Published: Elsevier, 2024-02-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_3acdb30624e8435b9f8cd36f55761a7d
042 |a dc 
100 1 0 |a Ruixue Liu  |e author 
700 1 0 |a Fengjuan Li  |e author 
700 1 0 |a Shuai Hao  |e author 
700 1 0 |a Dongyao Hou  |e author 
700 1 0 |a Xue Zeng  |e author 
700 1 0 |a He Huang  |e author 
700 1 0 |a Gautam Sethi  |e author 
700 1 0 |a Jun Guo  |e author 
700 1 0 |a Chenyang Duan  |e author 
245 0 0 |a Low-dose Olaparib improves septic cardiac function by reducing ferroptosis via accelerated mitophagy flux 
260 |b Elsevier,   |c 2024-02-01T00:00:00Z. 
500 |a 1096-1186 
500 |a 10.1016/j.phrs.2023.107056 
520 |a Sepsis is a dysregulated response to infection that can result in life-threatening organ failure, and septic cardiomyopathy is a serious complication involving ferroptosis. Olaparib, a classic targeted drug used in oncology, has demonstrated potential protective effects against sepsis. However, the exact mechanisms underlying its action remain to be elucidated. In our study, we meticulously screened ferroptosis genes associated with sepsis, and conducted comprehensive functional enrichment analyses to delineate the relationship between ferroptosis and mitochondrial damage. Eight sepsis-characterized ferroptosis genes were identified in sepsis patients, including DPP4, LPIN1, PGD, HP, MAPK14, POR, GCLM, and SLC38A1, which were significantly correlated with mitochondrial quality imbalance. Utilizing DrugBank and molecular docking, we demonstrated a robust interaction of Olaparib with these genes. Lipopolysaccharide (LPS)-stimulated HL-1 cells and monocytes were used to establish an in vitro sepsis model. Additionally, an in vivo model was developed using mice subjected to cecal ligation and perforation (CLP). Intriguingly, low-dose Olaparib (5 mg/kg) effectively targeted and mitigated markers associated with ferroptosis, concurrently improving mitochondrial quality. This led to a marked enhancement in cardiac function and a significant increase in survival rates in septic mice (p < 0.05). The mechanism through which Olaparib ameliorates ferroptosis in cardiac and leukocyte cells post-sepsis is attributed to its facilitation of mitophagy, thus favoring mitochondrial integrity. In conclusion, our findings suggest that low-dose Olaparib can improve mitochondrial quality by accelerating mitophagy flux, consequently inhibiting ferroptosis and preserving cardiac function after sepsis. 
546 |a EN 
690 |a Sepsis 
690 |a Olaparib 
690 |a Ferroptosis 
690 |a Mitophagy 
690 |a Cardiac function 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Pharmacological Research, Vol 200, Iss , Pp 107056- (2024) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S1043661823004127 
787 0 |n https://doaj.org/toc/1096-1186 
856 4 1 |u https://doaj.org/article/3acdb30624e8435b9f8cd36f55761a7d  |z Connect to this object online.